Physician profile
Samar Choubah
NPI 1588698245
$8,597.37
in general payments reported to CMS, 2019-2025
11 companies · $212 in 2025
The $212 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $500 · 2021: $60.29 · 2022: $247 · 2023: $6,983 · 2024: $388 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,725 · Travel and Lodging: $1,473 · Food and Beverage: $1,244 · Long Term Medical Supply Or Device Loan: $110 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,725.00 |
| Travel and Lodging | $1,472.58 |
| Food and Beverage | $1,243.83 |
| Long Term Medical Supply Or Device Loan | $109.98 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $7,029.75 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $791.95 | 2019-2025 | Freestyle Copilot, Freestyle Libre 3 |
| Novo Nordisk INC | $281.95 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| E.R. Squibb & Sons, L.L.C. | $205.23 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.97 | 2021-2024 | Jardiance |
| Esperion Therapeutics, INC. | $73.99 | 2021-2025 | Nexletol |
| Lifescan, INC. | $56.37 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.18 | 2023 | Farxiga |
| Alnylam Pharmaceuticals INC. | $19.99 | 2022 | |
| Amgen INC. | $15.72 | 2024 | Repatha |
| Janssen Pharmaceuticals, INC | $15.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samar Choubah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.